Navigation Links
Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy
Date:1/24/2013

r during radiation therapy could provide the health care team the ability to optimize treatment while reducing toxicity," says Steven J. Frank , M.D., Associate Professor of Radiation Oncology and Director of Advanced Technologies at MD Anderson. "Our collaborative research will focus on what this combination could mean for patients in the future."

"The development of a meaningful, yet complex innovation like the MRI-guided radiation therapy system can only be done in partnership with leading healthcare innovators, both from an industrial, as well as a clinical perspective," says Gene Saragnese , CEO Imaging Systems at Philips Healthcare. "As a leading innovator in cancer care, the University of Texas MD Anderson Cancer Center will bring their unique expertise to help realize the promise of more targeted cancer treatments and transform the way healthcare is delivered today."

Prior to the establishment of the research consortium, Elekta, Philips and the University Medical Center Utrecht have built and tested a prototype system that integrates a linear accelerator and a 1.5 Tesla MRI system. The success of these efforts has enabled the project to move to the next phase of development and testing by the select group of consortium partners.

Radiation therapy and medical imaging already play an essential role in treatment planning, delivery and after care, and are proven, cost-effective and safe methods for the treatment of individuals with cancer. Radiotherapy is a critical modality for cancer treatment, either as a frontline treatment or used with other modalities, such as chemotherapy. The procedure involves identifying cancerous tissue and irradiating it with high-energy radiation beams in a way that maximizes sparing of healthy tissues near the tumor.  

The integrated MRI-guided radiation therapy system is in development and not available for sale.

For further
'/>"/>

SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
2. Elekta President and CEO Tomas Puusepp Pledges Support in Addressing Global Cancer Challenge at World Cancer Leaders Summit in Montreal
3. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
4. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
5. Find New Cancer Treatments at cureLauncher
6. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
7. New Shared Synthetic Replikin Cancer Vaccines
8. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
9. Genetic basis of high-risk childhood cancer points to possible new drug treatment strategy
10. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
11. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
(Date:2/26/2015)... Innovation is more urgent than ever. ... of the world and transforming global markets in ... to health care, disruption is constantly underway. , ... trends shake the foundations of established business models, ... to survive the next wave of mega-change. , ...
(Date:2/26/2015)... February 26, 2015 According to a ... Biotechnology Market For Transgenic Crops (Corn, Soybean, Cotton and ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 – ... 15,300 million in 2012 and is expected to reach ... of 9.5% from 2013 to 2019. , Demand ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... EMERYVILLE, Calif., April 20 Bionovo, Inc. (Nasdaq: ... data on the nature of the active compound and mechanism ... presentation is being made at the 2009 conference of the ... the study concludes the following:, , ...
... Physicians Join World Class Group of AdvisorsSAN DIEGO, April ... of its Clinical Advisory Board, naming Donald H. Batts, ... the sixth and seventh members of the group of ... of Medicine at Michigan State University and ...
... dermatology company, acquired by GSK in deal valued ... have combined revenues of approximately $1.5 billion and ... and diversify GSK,s business, providing immediate new revenue ... (NYSE: GSK ) and Stiefel Laboratories ...
Cached Biology Technology:Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 3GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 4
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
... all types of yeast two-hybrid studies, including complex interaction ... Choice of two bait vectors for maximum flexibility ... Triple reporter strain NMY51 ensures ... Complete set of controls: pLexA-p53, pLexA-lamin C ...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: